Dr Reddys Laboratories Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Dr Reddys Laboratories has obtained an interim stay from the Telangana High Court regarding income tax reassessment proceedings tied to its merger with Dr. Reddys Holding Ltd, which involves a proposed demand exceeding ₹2,395 crore.

Dr Reddys Secures Stay on Tax Reassessment - 28 Aug, 2025

Dr. Reddy's Laboratories launched Colozo, a new constipation drug, while facing potential pricing pressures in the US market and securing a legal stay on tax reassessment.

Dr. Reddy's Launches New Drug Amid Market Challenges - 27 Aug, 2025

Dr. Reddy's Laboratories launched Linaclotide for chronic constipation and expressed optimism about upcoming GST reforms to enhance affordability in the pharma sector. However, the stock faced pressure due to concerns over US drug pricing cuts.

Dr. Reddy's Launches New Drug Amidst GST Optimism - 26 Aug, 2025

Dr. Reddy’s Laboratories announced participation in a virtual investor conference on August 21, 2025, while the stock gained 2.42%, marking its fifth consecutive rise.

Dr. Reddy’s Laboratories Engages Investors Amid Stock Gains - 13 Aug, 2025

Citi highlights a potential setback for Dr Reddys Laboratories and Aurobindo Pharma following USFDA approval of generic Iron Sucrose by competitors, indicating reduced market opportunities.

Citi Warns Dr Reddys of Competitive Setback - 12 Aug, 2025

Dr. Reddy's Laboratories received a positive EIR from the US FDA for its Telangana unit. Domestic institutions increased their stake, and the company reported a profit rise in Q1 FY26. Nomura forecasts stable US business despite competitive pressures.

Dr. Reddy's Laboratories Sees Stake Increase and Stable Outlook - 11 Aug, 2025

Dr. Reddy’s Laboratories received an Establishment Inspection Report from the USFDA for its Telangana facility, classified as VAI. Additionally, the NCLT approved the voluntary liquidation of its subsidiary Imperial, which will not significantly affect consolidated financials.

Dr. Reddy's Receives FDA Approval, Subsidiary Liquidated - 08 Aug, 2025

Dr Reddys Laboratories faced a decline of up to 2% as US President Trump announced potential steep hikes in tariffs on imported medicines, impacting the pharmaceutical sector.

Dr Reddys Shares Decline Amid Tariff Concerns - 06 Aug, 2025

Dr Reddys Laboratories Ltd is experiencing bearish trends, having broken below critical support levels. This situation raises concerns about future performance amid market challenges.

Dr Reddys Faces Bearish Trends and Support Breaks - 04 Aug, 2025

Dr. Reddy’s Laboratories released its Q1 FY26 earnings call, targeting double-digit sales growth. However, analysts downgraded the stock to SELL due to declining margins.

Dr. Reddy’s Laboratories Faces Downgrade Amid Growth Challenges - 30 Jul, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 12.89% to 13.61% in Jun 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Promoters holdings remained unchanged at 26.64% of holdings in Jun 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Revenue is down for the last 2 quarters, 9.05K Cr → 8.86K Cr (in ₹), with an average decrease of 2.1% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Foreign Institutions have decreased holdings from 25.75% to 25.32% in Jun 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Netprofit is down for the last 2 quarters, 1.59K Cr → 1.41K Cr (in ₹), with an average decrease of 11.0% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

In the last 7 days, DRREDDY stock has moved down by -0.5%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Retail Investor have decreased holdings from 10.15% to 10.00% in Jun 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Nifty50 Value 20

NIFTY 100

Nifty Healthcare

BSE 200

S&P BSE 100 LargeCap TMC

Nifty100 Eq Weig

Nifty100 Low Volatility 30

NIFTY PHARMA

BSE 100

BSE Healthcare

S&P BSE 250 LargeMidCap

S&P BSE SENSEX 50

S&P BSE Dividend Stability

S&P BSE Low Volatility

BSE 500

Nifty 500

NIFTY 50

S&P BSE 100 ESG

Nifty100 Quality

S&P BSE Largecap

BSE MFG

Nifty 200

Nifty LargeMidcap 250

Parag Parikh Flexi Cap Direct Growth

ICICI Prudential Value Fund Direct Plan Growth

Nippon India Large Cap Fund - Direct Plan - Growth Plan

ICICI Prudential Balanced Advantage Fund Direct Plan Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth

Dr Reddys Laboratories Ltd’s net profit jumped 1.85% since last year same period to ₹1,418.10Cr in the Q1 2025-2026. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -11% fall in its net profits since last 3-months.

Dr Reddys Laboratories Ltd Earnings Results

In the quarter ending March 2025, Dr Reddys Laboratories Ltd has declared dividend of ₹8.00 per share on 09 May 2025 - translating a dividend yield of 0.64%.

Name	Value	Action
MACD level (12,26)	0.37	Bearish
CCI (20)	-493.7	Bullish
RSI (14)	43.58	Neutral
Momentum (10)	-1.5	Bearish
ADI (14)	25.87	Bearish
Ultimate Oscillator (7,14,28)	67.88	Neutral

Name	Value	Action
SMA (20)	1262.12	Bearish
EMA (20)	1262.05	Bearish
VWMA (20)	1262.26	Bearish
SMA (50)	1261.17	Bearish
EMA (50)	1261.69	Bearish
SMA (200)	1262.26	Bearish
EMA (200)	1261.53	Bearish
KAMA (200)	1261.58	Bearish
DEMA (200)	1262.03	Bearish

Dr Reddys Laboratories Ltd (DRREDDY)

Summary

Overall

Oscillators

Moving Averages